Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost

Core Insights - Adia Nutrition Inc. is conducting an IRB-approved clinical study for children with Autism Spectrum Disorder (ASD) using umbilical cord blood-derived stem cell and exosome treatments, known as AdiaVita, combined with glutathione to evaluate improvements in ASD symptoms [1][2][3] Study Details - The study is a 24-month randomized, crossover trial targeting approximately 100 children aged 3-12 with confirmed ASD, with primary outcomes focused on changes in Autism Treatment Evaluation Checklist (ATEC) scores [2] - Participants in the active arm will receive three monthly infusions of AdiaVita plus glutathione, while the comparator arm will start with glutathione alone, with crossover options later [2] Previous Results - The trial builds on promising results from a 2025 study involving five children, where families reported significant symptom improvements, including one child with an ATEC score reduction of over 40 points [3] Participation and Costs - Enrollment requires a one-time fee of $12,000, covering all treatments and procedures for both phases of the study, with no monetary incentives offered [4] - The study is designed to ensure that all children receive the full treatment regardless of their initial group, provided they meet safety criteria [4] Global Participation - The trial welcomes children from across the United States and worldwide, reflecting the company's commitment to broad access to regenerative research [5] Company Commitment - The CEO of Adia Nutrition emphasized the company's dedication to transparent and ethical research aimed at supporting children with autism and their families [6] Company Overview - Adia Nutrition Inc. specializes in stem cell and regenerative products, operating through its lab division, Adia Labs LLC, and expanding its services to include insurance-billable wound care products [8] - The company generates revenue through service fees, product sales, and billing insurance for healthcare treatments, while also investing in aligned businesses [9]